Viking Therapeutics, Inc.VKTXNASDAQ
LOADING
|||
R&D Expense Growth Accelerating
Trending higher, above historical average.
Left:
||||
Year-over-year research & development expense growth
Latest
59.30%
↑ 138% above average
Average (9y)
24.94%
Historical baseline
Range
High:59.30%
Low:-68.65%
CAGR
NaN%
Modest growth trend
| Period | Value |
|---|---|
| 2024 | 59.30% |
| 2023 | 17.65% |
| 2022 | 20.57% |
| 2021 | 40.87% |
| 2020 | 35.54% |
| 2019 | 23.73% |
| 2018 | 38.56% |
| 2017 | 52.67% |
| 2016 | 29.19% |
| 2015 | -68.65% |